Topics:

Breast Cancer

Management of Young Breast Cancer Patients With de Novo Genetic Mutations

A 24-year-old woman presents to her primary care provider with a mass in her left breast. Examination confirms a 2.2-cm mass in the upper outer quadrant, with a single mobile axillary node that is firm to palpation.

Breast Cancer

Many women with breast cancer do not understand the details of their tumor characteristics or how they relate to specific treatment options, according to a new study.

New evidence reveals that risk prediction for breast cancer is imperative in women with atypical hyperplasia of breast tissue.

Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia.

Bisphosphonates or the monoclonal antibody denosumab, have the potential to profoundly affect the entire metastatic process, not just the growth of bone metastases.

There are still questions to be answered about the use of osteoclast inhibitors in the care of patients with breast cancer. The optimal duration and dosing schedule and how to improve treatment compliance are important issues to address.

We know that bisphosphonates prevent or delay skeletal-related events in breast cancer metastatic to bone, prevent or treat bone loss in patients receiving adjuvant aromatase inhibitor therapy, and decrease bone recurrences and breast cancer–related deaths when used in the adjuvant setting in postmenopausal women with early-stage breast cancer.

Two recently published studies suggest that PIK3CA mutations cannot be used as a predictive biomarker to guide therapy in HER2-positive breast cancer.

Pages

Subscribe to Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.